Optimizing the Treatment Continuum With a Molecular-Based Approach in HER2+ GI Cancers

Join us at ESMO GI 2024 for vital education on precision treatment strategies in HER2+ gastrointestinal cancers and elevate your clinical practice.

Live Meeting

Information

June 28, 2024

13:15 - 14:15 CEST

ICM – International Congress Center Messe Munich
Am Messesee 6, Room: 5 (Ground Floor), Munich 81829

Details

Presenters

Comments

Overview
Attend our ESMO Gastrointestinal Cancers Congress 2024 Industry Satellite Symposium to bridge gaps in managing HER2+ GI cancers. Gain insights to navigate accessibility challenges and effectively implement biomarker-based precision treatments. Learn to tailor therapeutic plans for HER2+ gastric, gastroesophageal junction, colorectal, and biliary tract cancers and optimize outcomes through interprofessional collaboration and adverse event management. Elevate your practice and ensure evidence-based care for HER2+ GI cancers.
Program Schedule*
13:00 – 13:15     Registration and Lunch
13:15 – 13:20     Welcome and Introductions
13:20 – 13:27     Optimizing Molecular Approaches in HER2+ GI Cancers
13:27 – 13:30     Audience Q&A, Panel Discussion, and Post-Assessment Questions
13:30 – 13:37     How a Biomarker-Driven Approach Is Needed Across Lines of Therapy in HER2+ Gastric/GEJ Cancer
13:37 – 13:40     Audience Q&A, Panel Discussion, and Post-Assessment Questions
13:40 – 13:47     Exploring New Opportunities to Improve Outcomes in Patients With HER2+ mCRC
13:47 – 13:50     Audience Q&A, Panel Discussion, and Post-Assessment Questions
13:50 – 13:57     The Evolution of HER2 Positivity in the Treatment of Biliary Tract Cancers
13:57 – 14:00     Audience Q&A, Panel Discussion, and Post-Assessment Questions
14:00 – 14:07     Safety Considerations of HER2-Directed Therapy in GI Cancers
14:07 – 14:10     Audience Q&A, Panel Discussion, and Post-Assessment Questions
14:10 – 14:15     Our Message Worth Sharing
*Subject to change
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Josep Tabernero, MD, PhD
Head, Medical Oncology Department
Director, Vall d’Hebron Institute of Oncology (VHIO)
Professor of Medicine, UVic-UCC
Vall d’Hebron University Hospital (HUVH)
Barcelona, Spain
Dr. Tabernero has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alentis Therapeutics, AstraZeneca, Aveo Oncology, Boehringer Ingelheim, Cardiff Oncology, CARSgen Therapeutics, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, hC Bioscience, Ikena Oncology, Immodulon Therapeutics, Inspirna Inc, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Takeda Oncology and Tolremo Therapeutics
Ownership: Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP
Faculty:
Sara Lonardi, MD
Chief, Oncology Unit 3
Veneto Institute of Oncology – IRCCS
Padua, Italy
No relevant financial relationships have been reported at this time.
Zev A. Wainberg, MD
Co-Director, UCLA GI Oncology Program
Professor of Medicine
University of California, Los Angeles
Santa Monica, CA, USA
No relevant financial relationships have been reported at this time.
Reviewers/Content Planners/Authors:
- Jorge Bacigalupo has nothing to disclose.
- Brad Bongiovanni, ND, has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Wendy Engelsma has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Develop strategies to overcome accessibility and implementation barriers for a collaborative, biomarker-based approach to the precision oncology treatment of GI cancers
- Individualize therapeutic planning and sequencing in patients with HER2+ gastric/GEJ cancers
- Identify the role of HER2-directed therapies to improve response and durability after disease progression on first-line therapy in patients with mCRC
- Contextualize the data on genomic profiling to guide treatment decisions in patients with HER2+ BTC
- Utilize interprofessional collaboration to hasten the recognition, monitoring, and management of adverse events seen with HER2-directed therapies in patients with GI cancers
Target Audience
This activity is designed to meet the educational needs of medical oncologists, pathologists, and other healthcare professionals who manage patients with gastrointestinal cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits^TM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 
Commercial Support
This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Presenters

Josep Tabernero, MD, PhD

Sara Lonardi, MD

Zev A. Wainberg, MD

Facebook Comments

Details

Presenters

Comments

Overview
Attend our ESMO Gastrointestinal Cancers Congress 2024 Industry Satellite Symposium to bridge gaps in managing HER2+ GI cancers. Gain insights to navigate accessibility challenges and effectively implement biomarker-based precision treatments. Learn to tailor therapeutic plans for HER2+ gastric, gastroesophageal junction, colorectal, and biliary tract cancers and optimize outcomes through interprofessional collaboration and adverse event management. Elevate your practice and ensure evidence-based care for HER2+ GI cancers.
Program Schedule*
13:00 – 13:15     Registration and Lunch
13:15 – 13:20     Welcome and Introductions
13:20 – 13:27     Optimizing Molecular Approaches in HER2+ GI Cancers
13:27 – 13:30     Audience Q&A, Panel Discussion, and Post-Assessment Questions
13:30 – 13:37     How a Biomarker-Driven Approach Is Needed Across Lines of Therapy in HER2+ Gastric/GEJ Cancer
13:37 – 13:40     Audience Q&A, Panel Discussion, and Post-Assessment Questions
13:40 – 13:47     Exploring New Opportunities to Improve Outcomes in Patients With HER2+ mCRC
13:47 – 13:50     Audience Q&A, Panel Discussion, and Post-Assessment Questions
13:50 – 13:57     The Evolution of HER2 Positivity in the Treatment of Biliary Tract Cancers
13:57 – 14:00     Audience Q&A, Panel Discussion, and Post-Assessment Questions
14:00 – 14:07     Safety Considerations of HER2-Directed Therapy in GI Cancers
14:07 – 14:10     Audience Q&A, Panel Discussion, and Post-Assessment Questions
14:10 – 14:15     Our Message Worth Sharing
*Subject to change
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Josep Tabernero, MD, PhD
Head, Medical Oncology Department
Director, Vall d’Hebron Institute of Oncology (VHIO)
Professor of Medicine, UVic-UCC
Vall d’Hebron University Hospital (HUVH)
Barcelona, Spain
Dr. Tabernero has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alentis Therapeutics, AstraZeneca, Aveo Oncology, Boehringer Ingelheim, Cardiff Oncology, CARSgen Therapeutics, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, hC Bioscience, Ikena Oncology, Immodulon Therapeutics, Inspirna Inc, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seattle Genetics, Servier, Sotio Biotech, Taiho, Takeda Oncology and Tolremo Therapeutics
Ownership: Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP
Faculty:
Sara Lonardi, MD
Chief, Oncology Unit 3
Veneto Institute of Oncology – IRCCS
Padua, Italy
No relevant financial relationships have been reported at this time.
Zev A. Wainberg, MD
Co-Director, UCLA GI Oncology Program
Professor of Medicine
University of California, Los Angeles
Santa Monica, CA, USA
No relevant financial relationships have been reported at this time.
Reviewers/Content Planners/Authors:
- Jorge Bacigalupo has nothing to disclose.
- Brad Bongiovanni, ND, has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Wendy Engelsma has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Bing-E Xu, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Develop strategies to overcome accessibility and implementation barriers for a collaborative, biomarker-based approach to the precision oncology treatment of GI cancers
- Individualize therapeutic planning and sequencing in patients with HER2+ gastric/GEJ cancers
- Identify the role of HER2-directed therapies to improve response and durability after disease progression on first-line therapy in patients with mCRC
- Contextualize the data on genomic profiling to guide treatment decisions in patients with HER2+ BTC
- Utilize interprofessional collaboration to hasten the recognition, monitoring, and management of adverse events seen with HER2-directed therapies in patients with GI cancers
Target Audience
This activity is designed to meet the educational needs of medical oncologists, pathologists, and other healthcare professionals who manage patients with gastrointestinal cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits^TM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research. 
Commercial Support
This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Presenters

Josep Tabernero, MD, PhD

Sara Lonardi, MD

Zev A. Wainberg, MD

Facebook Comments

ATTRv-PN: A Family Affair?
ATTRv-PN: A Family Affair?
MinuteCE®
ATTRv-PN: A Family Affair?
1.00 program credit
- John Berk, MD
- Noel Dasgupta, MD, FACC
1.00 program credit
ATTR Amyloidosis: Familial Vs Wild-Type
ATTR Amyloidosis: Familial Vs Wild-Type
MinuteCE®
ATTR Amyloidosis: Familial Vs Wild-Type
1.00 program credit
- Noel Dasgupta, MD, FACC
1.00 program credit
ATTRv-PN: A Complicated Disease With a Poor Prognosis
ATTRv-PN: A Complicated Disease With a Poor Prognosis
MinuteCE®
ATTRv-PN: A Complicated Disease With a Poor Prognosis
1.00 program credit
- John Berk, MD
- Sami Khella, MD
1.00 program credit
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
MinuteCE®
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
1.00 program credit
- Sami Khella, MD
- Marcia Waddington-Cruz, MD, PhD
1.00 program credit

Facebook Comments

Facebook Comments

Recommended

Title

Share on ReachMD